Heparin/Low Molecular Weight Heparin and Fondaparinux Pharmacology and Pharmacotherapy
In this knowledge-based continuing pharmacy education activity Dr Mary Jane Mattern, PharmD, CACP discusses the pharmacology and pharmacotherapy of heparin, low molecular weight heparin and fondaparinux.
Pharmacists who are interested in the management of patients on anticoagulation therapy and/or who are interested in starting pharmacy services for patients on anticoagulation therapy.
This activity is not accredited for technicians.
At the conclusion of the activity, pharmacists will be able to:
- Discuss the pharmacology of heparin, low molecular weight heparin and fondaparinux.
- Discuss the indications and contraindications for heparin, low molecular weight heparin and fondaparinux.
Mary Jane Mattern, PharmD, CACP
Pharmacist, William W. Backus Hospital, Norwich, CT
In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.
Mary Jane Mattern, PharmD, CACP has no actual or potential conflicts of interest associated with this presentation.
Click on the registration link to register for this activity. The cost is $7.50 if registering separately or 13 activities for $120.00 if bundling. See registration site for details.
This activity has been supported by an educational grant from CSL Behring
The University of Connecticut, School of Pharmacy, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 0.5 contact hour (0.05 CEU) will be awarded to pharmacists who view the presentation, pass the learning assessment with a grade of 70% or better and complete an evaluation. (ACPE #0009-0000-15-077-H01-P) As of January 1, 2013 credits will be electronically uploaded to CPE Monitor.
Initial release date: May 18, 2016
Planned expiration date: May 18, 2019